Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer.
Adoptive T cell immunotherapy strategies for the treatment of patients with ovarian cancer.
复制标题
DOI：
--
复制
发表时间：
2010
影响因子：
1.4
通讯作者：
A. Chekmasova;R. Brentjens
中科院分区：
文献类型：
--
作者：
A. Chekmasova;R. Brentjens
在妇科恶性肿瘤中，卵巢癌是癌症死亡的主要原因。尽管最初通过细胞减灭术和随后的联合化疗进行了成功的综合治疗，但大多数晚期疾病患者最终将复发并变得无法治愈。出于这个原因，迫切需要治疗这种恶性肿瘤的新的治疗方法。过继转移基因修饰的自体肿瘤反应性T细胞是一种很有前途的多种癌症的新型抗肿瘤治疗方法。T细胞可能会在体外进行基因修饰，以表达嵌合抗原受体(CARS)，这是一种针对特定肿瘤抗原的人造T细胞受体。因此，产生的T细胞被编程为识别肿瘤细胞。卵巢癌似乎特别适合这种治疗方法，因为这些肿瘤具有相对的免疫原性，可以诱导内源性T细胞反应。此外，这种内源性T细胞介导的免疫反应的程度与手术和化疗后患者的长期预后明显相关。为此，用于卵巢癌治疗的过继T细胞免疫治疗策略似乎特别有希望，目前正在临床前和临床环境下的几个中心进行研究。
Ovarian cancer is the leading cause of cancer death among gynecological malignances. Despite the initial successful multimodality therapy with cytoreductive surgery and subsequent combination chemotherapy, most patients with advanced disease will ultimately relapse and become incurable. For this reason novel therapeutic approaches for the treatment of this malignancy are urgently needed. Adoptive transfer of genetically modified autologous tumor-reactive T cells is a promising novel antitumor therapy for many cancers. T cells may be genetically modified ex vivo to express chimeric antigen receptors (CARs), which are artificial T cell receptors targeted to specific tumor antigens. The resulting T cells are thus programmed to recognize tumor cells. Ovarian carcinomas in particular appear to be suited to this therapeutic approach based on the fact that these tumors are relatively immunogenic, inducing an endogenous T cell response. Furthermore, the degree to which this endogenous T cell mediated immune response is evident correlates to long-term patient prognosis following surgery and chemotherapy. To this end, adoptive T cell immunotherapy strategies for the treatment of ovarian carcinomas appear to be particularly promising and are currently being investigated at several centers in both pre-clinical and clinical settings.